Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9416126B2 · kind B2 · utility
1Cited by
2References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 27, 2014 |
| Grant date | Aug 16, 2016 |
| Priority date | — |
| Expiry date | Feb 27, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.